All News

Intellectual property attorneys discuss the clarified requirements for when state failure-to-warn claims are pre-empted by FDA regulations after the Supreme Court Merck case.

Opinion remains divided regarding how aggressively MS should be treated. Some neurologists believe in the “treat early, treat aggressively” approach, whilst others prefer to “save” HE therapies until the more traditional platform therapies have failed.

Six ways medical affairs teams can build a stronger blueprint for collaboration in today’s changing environment.

There is a lack of push in the development of new antibiotics while anti-microbial resistance is a priority topic in healthcare policy and on the political agenda.

Steps for startups in tapping non-dilutive financing options.

Click the title above to open the Pharmaceutical Executive May 2019 issue in an interactive PDF format.

Following its economic rise in recent decades, driven by innovation across a wide variety of powerhouse industries, South Korea is setting its sights on the next generation of technological growth-including new strategies to globalize and industrialize the nation’s pharmaceutical and healthcare sector.

How drug developers can include strategy in R&D portfolio review to decide how to allocate resources across current and future projects.

As manufacturers look to commercialize new medicines, it is important to evaluate partners that can provide a fully integrated offering aligned to product performance goals and offer a seamless customer experience.

Each year, the success of cell and gene therapy becomes clearer, but what do we really know about it?

The lifeblood of our coverage are the many interviews we conduct with industry executives-and the unique stories and insights they provide. Here, I highlight excerpts from a selection of wide-ranging conversations from the past year.